Repligen Corp

RGEN

Equity

ISIN null / Valor 965900

NASDAQ (2025-12-19)

USD 162.38+2.95%

Repligen Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Repligen Corp is a company that provides technology solutions for the development and manufacture of various biopharmaceutical products, including plasmid DNA, viral vectors, mRNA, and new modalities like whole cells and cultivated meat. With over 15 years of experience and a track record of successful implementation in commercial processes, Repligen's XCell® ATF Technology stands out as a scalable and efficient method for upstream intensification. Additionally, the company offers the CTech™ FlowVPX® spectrophotometer system, designed to meet regulatory GMP requirements by providing reliable real-time concentration measurements throughout the downstream process.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Repligen Corp's Q3 2025 revenue rose from $155 million in Q3 2024 to $189 million, representing a 22% increase as reported and 18% organic growth. This robust performance was noted across all franchises and geographies, with double-digit gains driving the positive trend.

Order Acceleration

The company reported sequential increases in orders, with a year-over-year rise of over 20%, indicating strong market demand and confidence in its innovative product offerings, such as the new SoloVPE® PLUS.

Improved Profitability

Q3 2025 saw notable earnings improvements with GAAP income climbing to $17 million from a loss of $8 million in the previous year and GAAP net income turning positive to $15 million compared to a $1 million loss, alongside enhanced gross margins.

Positive Guidance Update

Building on its strong quarterly performance and solid year-to-date growth, Repligen Corp raised its full-year revenue guidance to a range of $729 million to $737 million. This guidance reflects expected non-COVID organic growth of approximately 14% to 15.5%, and further increases investor confidence in the company's growth trajectory.

Summarized from source with an LLMView Source

Key figures

10.8%1Y

-0.02%3Y

-16.3%5Y

Performance

51.5%1Y

49.6%3Y

50.5%5Y

Volatility